X0306 4 2020-02-24 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001564621 Moriarty John B C/O PORTOLA PHARMACEUTICALS, INC. 270 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, General Counsel Performance Stock Unit 2020-02-24 4 A 0 73125 0.00 A 2023-02-24 Common Stock 73125 73125 D Each performance stock unit (PSU) represents a contingent right to receive one (1) share of the Issuer's common stock. One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. Any PSUs not yearned on the three (3) year anniversary of the grant date will expire. /s/ Mike Ouimette, as attorney-in-fact 2020-02-26